Trial Profile
A phase 1b/2 study of ABT-510 (thrombospondin analogue) in patients with advanced head and neck cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs ABT 510 (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Jun 2008 Status changed from in progress to completed.
- 10 Aug 2007 Status changed from recruiting to in progress.
- 19 Aug 2005 New trial record.